InfuSystem Holdings Inc (INFU) 2026 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and welcome to the InfuSystem Holdings, Inc., reports first quarter fiscal year 2026 financial results conference call. (Operator Instructions) Please note, this event is being recorded.

    大家好,歡迎參加 InfuSystem Holdings, Inc. 2026 會計年度第一季財務業績電話會議。(接線員指示) 請注意,本活動將被錄音。

  • I would now like to turn the conference over to Glen Akselrod, Investor Relations. Please go ahead.

    現在我想把會議交給投資人關係的 Glen Akselrod。請開始。

  • Glen Akselrod - Investor Relations

    Glen Akselrod - Investor Relations

  • Good morning, and thank you for joining us today to review InfuSystem's first quarter 2026 financial results ended March 31, 2026. With us today on the call are Carrie Lachance, Chief Executive Officer; and Barry Steele, Chief Financial Officer. After the conclusion of today's prepared remarks, we will open the call for questions.

    各位早安,感謝各位今天加入我們,一同回顧 InfuSystem 截至 2026 年 3 月 31 日止的 2026 年第一季財務結果。今天與會的有執行長 Carrie Lachance,以及財務長 Barry Steele。在今天的準備發言結束後,我們將開放提問。

  • Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of InfuSystem during this conference call constitute forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995. Except for statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under the Risk Factors in the documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended December 31, 2025.

    在開始準備發言之前,我想提醒各位,InfuSystem 管理團隊在本次電話會議中所作的某些陳述,依據 1995 年《私人證券訴訟改革法》(Private Securities Litigation Reform Act of 1995) 的定義,構成前瞻性陳述。除歷史事實陳述外,本次電話會議可能包含涉及風險與不確定性的前瞻性陳述,其中部分已在公司向美國證券交易委員會(SEC)提交的文件之「風險因素」中詳述,包括截至 2025 年 12 月 31 日止年度的 Form 10-K 年報。

  • Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. InfuSystem does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law.

    前瞻性陳述僅反映其作出當日的情況。公司無法保證此等前瞻性陳述將被證實為正確。除法律要求外,InfuSystem 不承擔且明確否認任何更新任何前瞻性陳述之義務。

  • Now, I'd like to turn the call over to Carrie Lachance, Chief Executive Officer of InfuSystem. Carrie?

    現在,我想把電話交給 InfuSystem 執行長 Carrie Lachance。Carrie?

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Thank you, Glen, and good morning, everyone. Welcome to InfuSystem's first quarter fiscal year 2026 earnings call. Thank you all for joining us today. I will provide a first quarter overview highlighting key initiatives and updating our progress on strategic priorities. Then Barry will provide a detailed summary of our financial results. I will then come back with some closing comments before opening the line to questions.

    謝謝你,Glen,各位早安。歡迎參加 InfuSystem 2026 會計年度第一季法說會。感謝各位今天加入我們。我將提供第一季概覽,重點說明關鍵計畫並更新我們在策略優先事項上的進展。接著 Barry 將就我們的財務結果提供詳細摘要。之後我會再回來做一些結語,然後開放提問。

  • Today, we reported first quarter of 2026 revenue of $33.7 million. This represented a decline from our prior year of just over $1 million on a GAAP basis, but a 1.7% increase on a pro forma basis. The GAAP reduction was mainly driven by the restructuring of our biomedical services contract with GE Healthcare, which reduced revenue by $1.6 million during the first quarter and is the basis for the adjustment to providing pro forma revenue.

    今天我們公布 2026 年第一季營收為 3,370 萬美元。以 GAAP 基礎計算,較去年同期下滑略高於 100 萬美元,但以備考(pro forma)基礎計算則成長 1.7%。GAAP 營收下滑主要是因我們與 GE Healthcare 的生醫服務合約進行重整,該重整在第一季使營收減少 160 萬美元,亦為我們調整並提供備考營收的依據。

  • As we reported on our last two earnings calls, this restructuring improves our earnings because it allowed for an even larger reduction in direct contract expenses. Despite the decline in revenue, we generated approximately $6.4 million in adjusted EBITDA this quarter, roughly in line with the prior year, resulting in a modest improvement in adjusted EBITDA margin to 18.9%, up from 18.2% in the first quarter last year.

    如同我們在前兩次法說會所提到的,這次重整改善了我們的獲利,因為它使直接合約成本得以更大幅度下降。儘管營收下滑,本季我們仍創造約 640 萬美元的調整後 EBITDA,與去年同期大致相當,使調整後 EBITDA 利潤率小幅提升至 18.9%,高於去年第一季的 18.2%。

  • Behind these results are two very important initiatives that warrant a progress update. First, we continue to expand our Wound Care products category. During the first quarter, Wound Care net revenue came in at $2.1 million. While the number is still small, representing only 6% of our total quarterly revenue, we are excited about the growth rate, which was more than double the prior year at just under 112%.

    支撐這些成果的背後,有兩項非常重要的計畫值得向各位更新進度。第一,我們持續擴大傷口照護(Wound Care)產品類別。第一季傷口照護淨營收為 210 萬美元。雖然金額仍不大,僅占我們單季總營收的 6%,但我們對其成長速度感到振奮,年增率超過一倍,接近 112%。

  • About 60% of the growth came from our compression device product line, which we recently added during the third quarter of last year. This product line was expanded with the launch of a second compression device supplier during the first quarter of 2026.

    約 60% 的成長來自我們的加壓裝置(compression device)產品線,該產品線是我們在去年第三季新增的。隨著我們在 2026 年第一季推出第二家加壓裝置供應商,該產品線也進一步擴充。

  • The first manufacturer relationship brought us pneumatic compression devices, or PCDs, which use sequential compression technology to treat patients with lymphedema and similar disease states. The additional supplier now adds Adjustable Compression Wraps, which feature [Vicryl] closures that are easier for patients with limited mobility as compared to traditional products such as compression stockings.

    第一家製造商合作關係為我們帶來氣動加壓裝置(pneumatic compression devices,PCDs),其使用序列式加壓技術(sequential compression technology)來治療淋巴水腫及類似疾病狀態的患者。新增的供應商則帶來可調式加壓包覆帶(Adjustable Compression Wraps),其採用 [Vicryl] 黏扣設計,對於行動受限的患者而言,相較於傳統產品(如彈性襪)更容易使用。

  • Adjustable Compression Wraps represent a significant expansion of our addressable market as they serve a diverse patient demographic ranging from simple post-surgical recovery to lifelong management of chronic disorders that may not qualify for other treatments, such as PCDs.

    可調式加壓包覆帶大幅擴展了我們可服務的市場,因其可涵蓋多元的患者族群,從單純的術後復原到需終身管理的慢性疾病;其中部分患者可能不符合其他治療(例如 PCDs)的適用條件。

  • The second key initiative I'd like to update you on reached a very important milestone during the first quarter. Sunday, March 1, 2026, was a very busy day for the team here at InfuSystem. After 20 months of intense meetings, data compilation, and endless process analysis and testing, live transactions started running in our newly installed enterprise resource planning system, our ERP.

    第二項我想向各位更新的關鍵計畫,在第一季達成了一個非常重要的里程碑。2026 年 3 月 1 日(星期日)對 InfuSystem 團隊而言是非常忙碌的一天。在經過 20 個月密集會議、資料彙整,以及無止盡的流程分析與測試後,我們新導入的企業資源規劃系統(enterprise resource planning system,ERP)開始進行正式上線交易(live transactions)。

  • As is fairly typical for these type of projects, the first month wasn't entirely seamless, and we continue to work out initial bugs and make the necessary adjustments to stabilize the system. However, I'm happy to report that we successfully cleared the go-live hurdle and are charging forward to secure the benefit of the new system that we have been looking forward to implementing over these many months.

    如同此類專案相當常見的情況,第一個月並非完全順暢,我們仍持續排除初期錯誤並進行必要調整,以穩定系統。不過,我很高興向各位報告,我們已成功跨越上線門檻,並正全力向前,確保取得這套新系統在過去數月中我們一直期待實現的效益。

  • This marks a very significant milestone for InfuSystem. After putting this application in place and retiring several legacy systems, much of our data is now integrated, workflows are connected, and the many processes supporting our various business lines run through a common platform, not multiple disparate systems.

    這對 InfuSystem 而言是一個非常重大的里程碑。在導入此應用並汰換數個舊有系統後,我們的大部分資料如今已整合,工作流程彼此串接,支援各條業務線的眾多流程也都在同一平台上運行,而非分散於多個彼此不相容的系統。

  • While we continue to make final adjustments, resolve open items on the punch list, and get over the learning curve, we are starting to focus on capturing the benefits that we anticipate will start to pay back our investment. These benefits are expected to come in many forms and include improved ability to complete tasks with greater productivity, better cost and margin analysis to focus on high return cost optimization initiatives. Improved visibility to support pricing decisions, improved utilization of our medical device fleet, and optimization of working capital levels.

    在我們持續進行最後調整、解決待辦清單上的未結事項並度過學習曲線的同時,我們也開始聚焦於取得我們預期將可回收投資的效益。這些效益預期將以多種形式呈現,包括提升完成任務的能力與生產力、更佳的成本與毛利分析以聚焦高報酬的成本優化計畫。並提升可視性以支援定價決策、提高我們醫療設備機隊的使用率,以及最佳化營運資金水準。

  • Additionally, we are already working to identify system enhancements and will implement those that provide the fastest payback and highest investment returns. As we look forward to the rest of the year and after adjusting for the expected $7.1 million lower annual revenue related to the GE Healthcare contract restructuring, on a pro forma basis, we continue to anticipate annual revenue growth in the range of 6% to 8%.

    此外,我們已著手辨識系統強化項目,並將優先導入那些回收期最快且投資報酬最高的改善。展望今年其餘時間,在就 GE Healthcare 合約重整所預期帶來的年度營收減少 710 萬美元進行調整後,以備考(pro forma)基礎計算,我們仍預期全年營收成長將落在 6% 至 8% 的區間。

  • Additionally, we continue to anticipate that our adjusted EBITDA margin will remain in the low to mid-20% range. This is inclusive of the impact of costs related to our ongoing information technology systems upgrade. We are excited about the opportunities ahead and will look to update you again in future quarters.

    此外,我們仍預期調整後 EBITDA 利潤率將維持在 20% 出頭至 20% 中段的區間。此預期已包含我們持續進行資訊科技系統升級所帶來的成本影響。我們對未來的機會感到振奮,並期待在未來季度再次向各位更新。

  • Now, I'll turn it over to Barry for a detailed review of the first quarter financial results. Barry?

    現在,我把時間交給 Barry,請他詳細回顧第一季的財務結果。Barry?

  • Barry Steele - Chief Financial Officer, Executive Vice President

    Barry Steele - Chief Financial Officer, Executive Vice President

  • Thank you, Carrie, and thank you everyone on the call for joining us today. I'm going to give details of the current quarter's results, provide a few updates on the ERP spend, and update you on our current financial position and how it changed during the quarter. Now, let me start with our financial results for the period.

    謝謝你,Carrie,也謝謝今天參與電話會議的各位。我將說明本季的業績細節,提供幾項 ERP 支出更新,並向各位更新我們目前的財務狀況以及本季期間的變化。現在,讓我先從本期的財務結果開始。

  • During the first quarter of 2026, our net revenue totaled $33.7 million, representing a $1 million or 3% decrease from the prior year first quarter. Adjusting for the GE Healthcare contract restructuring, our pro forma net revenue grew by 1.7%.

    在 2026 年第一季,我們的淨營收合計為 3,370 萬美元,較去年同期第一季減少 100 萬美元或 3%。若排除 GE Healthcare 合約重整的影響,我們的備考(pro forma)淨營收成長 1.7%。

  • Patient services net revenue increased by $1.3 million, or 6.4%, and included increased patient treatment volumes in Oncology and Wound Care. Oncology net revenue increased by approximately $450,000, or 2.4%, and Wound care treatment volumes revenue grew by $1.1 million, which represented an increase of nearly 112%, driven by compression devices, as Carrie mentioned.

    病患服務淨營收增加 130 萬美元(或 6.4%),其中包含腫瘤科與傷口照護的病患治療量增加。腫瘤科淨營收約增加 45 萬美元(或 2.4%),而傷口照護治療量相關營收增加 110 萬美元,增幅接近 112%,主要由加壓裝置帶動,如 Carrie 所提。

  • Device Solutions net revenue decreased by $2.3 million or 17%. Nearly 70% of the decrease was attributable to the GE Healthcare contract restructuring. The remaining amount of the decrease, which was about $760,000, was due to lower rental revenues and lower equipment sales of $432,000 and $1 million respectively. Both of these decreases are related to a large customer rental buyout that began in the prior year. The buyout was started during the prior year first quarter.

    Device Solutions 淨營收減少 230 萬美元或 17%。其中近 70% 的降幅可歸因於 GE Healthcare 合約重整。其餘約 76 萬美元的降幅,則來自租賃營收下降 43.2 萬美元以及設備銷售下降 100 萬美元。這兩項下滑都與一位大型客戶的租賃買斷案有關,該案始於去年。該買斷案於去年第一季啟動。

  • Elevated the amount of equipment sales in the prior year and reduced quarterly rental revenues during the subsequent quarters, including the current three-month period. These reductions were partially offset by an increase in the non-GE-related biomedical services revenue of $340,000 and higher disposal medical supplies revenue, which also increased by $340,000.

    這在去年提高了設備銷售金額,並在其後各季(包含本期三個月期間)降低了每季租賃營收。上述降幅部分被非 GE 相關的生醫服務營收增加 34 萬美元,以及醫療耗材處置營收增加 34 萬美元所抵銷。

  • Breaking down the biomedical services revenue a little further, we see that our field-based services grew by nearly $600,000 after adjusting out the GE Healthcare revenue decline. This underlying increase demonstrates partial success in replacing lost GE revenue. Furthermore, as you will see when I get to discussing gross margin, the benefit to earnings for this trade-off was rewarding.

    進一步拆解生醫服務營收,在剔除 GE Healthcare 營收下滑後,我們的外勤服務成長近 60 萬美元。這項基本面成長顯示我們在替代流失的 GE 營收方面取得部分成效。此外,當我談到毛利率時各位會看到,這項取捨對獲利的貢獻相當可觀。

  • Despite the decrease in net revenue, gross profit for the first quarter of 2026 was $19.7 million, representing an increase of $515,000 or 3% over the prior year first quarter. The gross margin percentage at just over 58% increased by 3.2% from the prior year amount. At the segment level, patient services gross profit increased by $1.3 million and gross margin increased by 1.3% to 64.8%, driven by the higher sales and reduced pump disposal and maintenance expenses.

    儘管淨營收下降,2026 年第一季毛利為 1,970 萬美元,較去年同期第一季增加 51.5 萬美元或 3%。毛利率略高於 58%,較去年同期提高 3.2 個百分點。以事業部門來看,病患服務毛利增加 130 萬美元,毛利率提高 1.3 個百分點至 64.8%,主要受較高銷售額以及幫浦處置與維護費用降低所帶動。

  • Device Solutions gross profit declined by $623,000, mainly due to the lower amounts of rental and equipment sales revenue, but the gross margin increased by 3.4% to 46.3%. The greatest contributor to this improvement was the aforementioned trade-off between GE Healthcare and smaller field service projects, which, despite resulting in an overall decline in revenue, netting to just over $1 million, contributed nearly $400,000 of additional gross margin, resulting in a more than 7% increase in device services gross margin. This benefit was partially offset by unfavorable revenue mix and higher wage and employee health care expenses, which reduced the gross margin by nearly 2% and 2.5%, respectively.

    Device Solutions 毛利下滑 62.3 萬美元,主要因租賃與設備銷售營收較低,但毛利率提高 3.4 個百分點至 46.3%。此改善的最大貢獻來自前述在 GE Healthcare 與較小型外勤服務專案之間的取捨;儘管整體營收淨減逾 100 萬美元,卻帶來近 40 萬美元的額外毛利,促使裝置服務毛利率提高超過 7 個百分點。此效益部分被不利的營收組合以及較高的薪資與員工醫療保健費用所抵銷,分別使毛利率降低近 2 個百分點與 2.5 個百分點。

  • Selling, general and administrative expenses for the first quarter of 2026 totaled $17.9 million and was $418,000 or 2.2% lower than the prior year first quarter amount. The prior year amount included a non-recurring expense related to the departure of our former CEO of $1 million. Additional reductions included a $300,000 reduction in the accrual for management bonuses, lower accounting fees totaling $200,000, and $100,000 in reduced travel expenses. These decreases were partially offset by increases in other expenses, including $400,000 in increased expenses related to information technology and business applications upgrades, including the replacement of the company's ERP that Carrie discussed.

    2026 年第一季銷售、一般及管理費用合計為 1,790 萬美元,較去年同期第一季減少 41.8 萬美元或 2.2%。去年同期金額包含一筆與前任 CEO 離任相關的一次性費用 100 萬美元。其他減少項目包括管理獎金提列減少 30 萬美元、會計費用降低合計 20 萬美元,以及差旅費用減少 10 萬美元。上述降幅部分被其他費用增加所抵銷,其中包括與資訊科技及商業應用升級相關的費用增加 40 萬美元,包含 Carrie 所提到的公司 ERP 更換。

  • Additional personnel directly related to increased patient services net revenue, including revenue cycle personnel pulling $300,000, a $100,000 increase in stock-based compensation expenses, and cost inflation impacts from increased employee wage rates and higher healthcare expenses totaling $400,000.

    另外,因病患服務淨營收增加而直接新增的人員成本(包含收入循環相關人員)為 30 萬美元、以股份為基礎之薪酬費用增加 10 萬美元,以及因員工薪資調升與醫療保健費用提高所造成的成本通膨影響合計 40 萬美元。

  • The ERP system upgrade project expenses were higher during the current period due to the higher intensity of activities related to the go-live phase of the project, which, as Carrie mentioned, occurred on March 1, 2026. While additional costs are expected to be incurred during the post-go-life phase to support system stabilization and enhancement activities, product expenses are expected to begin to taper down during the future quarterly periods.

    ERP 系統升級專案費用在本期較高,原因是專案上線(go-live)階段的活動強度較高;如 Carrie 所提,上線發生於 2026 年 3 月 1 日。雖然在上線後(post-go-live)階段,為支援系統穩定與強化活動,仍預期會發生額外成本,但專案費用預期將在 2026 年後續各季開始逐步下降。

  • Similar to impacts of gross margin and selling and marketing expenses, higher wages were the result of typical annual merit and cost of living increases. However, the increase in cost of healthcare benefits, which in total increased by $374,000 during the quarter, were significantly higher than the increases experienced in the prior years.

    與毛利率及銷售與行銷費用的影響類似,較高的薪資主要來自例行性的年度績效調薪與生活成本調整。然而,醫療保健福利成本的增加(本季合計增加 37.4 萬美元)明顯高於過去幾年的增幅。

  • Adjusted EBITDA during the 2026 first quarter was $6.3 million, which, despite the lower net revenue, was about the same amount as the prior year first quarter. This represented 18.9% of net revenue for 2026, which was slightly above the prior year rate of 18.2%. These amounts included the spending on our ERP project, which, again, is expected to start to decrease by the end of the second quarter here in 2026.

    2026 年第一季調整後 EBITDA 為 630 萬美元,儘管淨營收較低,仍與去年同期第一季大致相當。此金額占 2026 年淨營收的 18.9%,略高於去年同期的 18.2%。上述金額包含我們 ERP 專案的支出;同樣地,該支出預期將在 2026 年第二季末開始下降。

  • Now, a few comments on our financial position and capital reserves. During the first quarter, we generated operating cash flow of $970,000, which was $817,000 less than the prior year first quarter, mainly due to higher increases in working capital in 2026.

    接著簡要說明我們的財務狀況與資本準備。第一季我們產生的營運現金流為 97 萬美元,較去年同期第一季少 81.7 萬美元,主要因 2026 年營運資金增加幅度較大。

  • Our net capital expenditures were $1.3 million during the 2026 first quarter, which represented a decrease from $2.6 million spent during 2025. This decrease was attributable to our overall capital spending requirements being lower as compared to amounts in prior years, as the sources of our revenue growth have been more weighted towards less capital-intensive revenue sources, including additional Wound Care revenues. We expect moderate amounts of capital expenditures to continue in 2026, similar to 2025.

    2026 年第一季我們的淨資本支出為 130 萬美元,較 2025 年的 260 萬美元下降。此下降歸因於相較前幾年,我們整體資本支出需求較低,因為營收成長來源更偏向資本密集度較低的收入來源,包括額外的傷口照護營收。我們預期 2026 年將持續維持適度的資本支出水準,與 2025 年相近。

  • We remain well-positioned to fund continued net revenue growth with a strong cash flow from operations backed by significant liquidity reserves available from our revolving line of credit and manageable leverage and debt service requirements. Our net debt increased slightly by $1.1 million during the quarter, and we repurchased just over $800,000 of our common stock during the quarter through our stock repurchase authorization.

    我們仍處於有利位置,憑藉強勁的營運現金流,並由我們循環信用額度所提供的可用重大流動性儲備支撐,以及可控的槓桿水準與債務償付需求,為持續的淨營收成長提供資金支持。本季我們的淨負債小幅增加110萬美元,且我們透過股票回購授權於本季回購了略高於80萬美元的普通股。

  • Our available liquidity continued to be strong and totaled just over $57 million as of March 31, 2026. At that time, our ratio of net debt to adjusted EBITDA was a modest 0.56 times. Our debt consists of $20 million in borrowings on our $75 million revolving line of credit with no term payment requirements and a maturity date of July 2030. We continue to benefit from an outstanding interest rate swap, which fixes our interest rate on the $20 million of our outstanding borrowings. At a below-market rate of 3.8% until April of 2028.

    截至2026年3月31日,我們可用流動性仍然強勁,合計略高於5,700萬美元。當時,我們的淨負債對調整後EBITDA比率為0.56倍,屬於溫和水準。我們的債務包括在7,500萬美元循環信用額度下借入的2,000萬美元,無需分期本金償付,且到期日為2030年7月。我們持續受惠於一項優異的利率交換合約,將我們未償借款中2,000萬美元的利率固定。該固定利率在2028年4月之前為低於市場的3.8%。

  • I will now turn the call back over to Carrie.

    我現在把電話交回給Carrie。

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Thanks, Barry. As I reflect on the progress we have made during the first quarter, the updates shared with you today, and what we are focused on as we move through the rest of 2026, I hope you will agree that we continue to be diligent in pursuing the strategic priorities previously laid out for our shareholders. Those priorities are to execute with discipline, deliver profitable growth and drive long-term value creation for shareholders.

    謝謝你,Barry。回顧第一季我們所取得的進展、今天與各位分享的更新,以及我們在2026年剩餘期間的重點工作,我希望各位會同意,我們仍持續審慎地推進先前向股東所闡明的策略優先事項。這些優先事項包括:以紀律執行、實現具獲利性的成長,並為股東創造長期價值。

  • Operator, we are ready for the Q&A portion of the call.

    接線員,我們已準備好進入本次電話會議的問答環節。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Anderson Schock, B. Riley.

    Anderson Schock,B. Riley。

  • Anderson Schock - Equity Analyst

    Anderson Schock - Equity Analyst

  • Hi, good morning. Thank you for taking our questions and congrats on all the progress. So first, the DRP went live at the start of March. Can you talk about how the conversion is going and have you seen any billing or collections disruption or impact on the working capital? And when do you expect the cost step down to begin showing in the P&L? Is it more second or third quarter weighted?

    嗨,早安。謝謝你們回答我們的問題,也恭喜你們取得各項進展。首先,DRP在3月初上線。能否談談轉換進度如何?你們是否看到任何開立帳單或收款方面的中斷,或對營運資金造成影響?另外,你們預期成本下降何時會開始反映在損益表中?是第二季或第三季的比重較高?

  • Barry Steele - Chief Financial Officer, Executive Vice President

    Barry Steele - Chief Financial Officer, Executive Vice President

  • Yes, I'll take that one, Carrie. As any ERP implementation, we definitely had our glitches that we dealt with, affected a number of different areas. We do not think that anything is going to cause any disruptions in our cash flow or billings or anything like that. So I think we're pretty good. It's more kind of working out some of our processes and making them as efficient as they are expected to be. As far as the long-term outlook for the impact for the system, Carrie mentioned a lot of the benefits that we can see sort of from a summary perspective.

    好的,Carrie,這題我來回答。如同任何ERP導入,我們確實遇到一些需要處理的瑕疵,影響到多個不同領域。我們不認為這些問題會造成現金流、開立帳單或其他方面的中斷。所以我認為整體狀況相當不錯。目前比較像是在梳理部分流程,讓它們達到預期的效率。至於系統對長期展望的影響,Carrie已從概括角度提到許多我們可見的效益。

  • We believe that struggling through the learning curve, still fixing a few glitches. By the end of the year, we'll be able to, I think, articulate very well and have plans in place for going and getting the cost savings that the system should be able to provide to us. And I believe that next year, we'll see some of that actually pay off and we'll start seeing the expenses that we have today reverse to the actual proceeds from the reduced reduction costs.

    我們認為在度過學習曲線、並持續修正少數瑕疵之後,到今年年底,我們將能夠非常清楚地說明,並制定計畫去取得該系統應能為我們帶來的成本節省。我相信明年我們會看到部分效益實際落地,並開始看到我們目前的費用回轉,反映為成本降低所帶來的實際成果。

  • Anderson Schock - Equity Analyst

    Anderson Schock - Equity Analyst

  • Okay, got it. Thank you. And then on the last call, you indicated oncology would begin migrating to the Apollo-based RCM platform in the back half of the year. Now that the ERP is live, is the timeline for oncology RCM migration shifted?

    好的,了解。謝謝。另外,在上次電話會議中,你們提到腫瘤科將在今年下半年開始遷移至以Apollo為基礎的RCM平台。現在ERP已上線,腫瘤科RCM遷移的時程是否有調整?

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Yeah, no, it should still be -- thanks for the question, Anderson. It should still be kind of second-half of the year. That is some of the progress and why we decided to be second-half of the year and delay that just a little bit to get the ERP behind us and some of those continued kind of processes through the ERP improvements in the system. So it is on track to hopefully finish up by the end of the year, but we've started to begin that process.

    是的,沒有,時程應該仍然會是——謝謝你的提問,Anderson。應該仍會在今年下半年左右。這也是我們之所以決定放在下半年、並稍微延後一點的原因之一,好讓我們先把ERP上線這件事處理完,並持續推進ERP相關流程與系統的改善。因此進度仍在軌道上,希望能在年底前完成,不過我們已經開始啟動該流程。

  • Barry Steele - Chief Financial Officer, Executive Vice President

    Barry Steele - Chief Financial Officer, Executive Vice President

  • I would just add, we use a lot of internal resources for the ERP. They're a lot of the same resources that this other conversion will require, so that's why we had to stagger them.

    我補充一下,我們在ERP上投入了大量內部資源。而這次另一項轉換也需要許多相同的資源,因此我們必須把兩者錯開進行。

  • Anderson Schock - Equity Analyst

    Anderson Schock - Equity Analyst

  • Okay. Got it. That's helpful. And then on the new oncology customers signed in the back half of last year, could you give us a sense of the typical ramp curve for a new hospital system? And specifically, how much of the contract volume signed in the back half of '25 has shown up in the first quarter versus what's still to come?

    好的。了解。這很有幫助。另外,關於去年下半年簽下的新腫瘤科客戶,你們能否說明新醫院系統的典型導入爬坡曲線?具體而言,2025年下半年簽約的合約量,有多少已在第一季反映出來?還有多少尚待後續顯現?

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Yeah, we can see sometimes in a new oncology account, they could have several hundred patients. A lot of times that process will -- the newer patients will start to come on board, but the older patients that are on their older device, say an elastomeric, for instance, they'll finish out their continued therapy and the rest of their cycles on that same device. So it can take from, a month or two, depending on how many new patients they have through a few months. We are pretty well on board with that newer customer from last year.

    是的,我們有時會看到新的腫瘤科客戶帳戶可能有數百名病患。很多時候流程會是——新病患會開始導入,但既有病患仍使用他們原本的裝置,例如彈性體(elastomeric)之類,會先把既有療程與剩餘週期在同一裝置上完成。因此導入時間可能從一兩個月(取決於新病患數量)到數個月不等。我們對於去年新增的那位新客戶,目前導入進展相當順利。

  • Anderson Schock - Equity Analyst

    Anderson Schock - Equity Analyst

  • Okay, got it. Thank you for taking the questions.

    好的,了解。謝謝你們回答問題。

  • Operator

    Operator

  • Jim Sidoti, Sidoti & Company.

    Jim Sidoti,Sidoti & Company。

  • James Sidoti - Analyst

    James Sidoti - Analyst

  • Hi, good morning, and thanks again for taking questions. So with regards to lymphedema, this isn't the first time you've been in that market. Why do you think you're doing better this time than in previous attempts?

    嗨,早安,也再次感謝你們接受提問。關於淋巴水腫(lymphedema),這並不是你們第一次進入這個市場。你們認為這次為何能比過去的嘗試做得更好?

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Yeah, it's a great question, Jim. Good morning. The difference today is really our partnerships. So we have a new partner that came on board, as we mentioned, third quarter -- fourth quarter, excuse me, of last year, really strong partnership with them. They bring us the PCDs.

    是的,Jim,這是個很好的問題。早安。目前的差異主要在於我們的合作夥伴關係。如我們所提到的,我們在去年第三季——更正,第四季——引入了一位新的合作夥伴,與他們建立了非常強健的合作關係。他們為我們帶來PCD。

  • The partnership that we had a few years ago when we tried this, we need the paperwork, we need clean referrals, we need all of the ability to build those claims and we weren't receiving that during that prior start of our PCD and compression go live.

    幾年前我們嘗試時的那段合作關係中,我們需要文件資料、需要乾淨的轉介(referrals)、需要所有能夠建立理賠申請(claims)的要件,但在先前PCD與壓縮產品上線初期,我們並未收到這些資料。

  • And so the new partner that we received or that we onboarded in Q4 of last year has been very strong. We continue to grow and stabilize and even improve that relationship. As well as Q1 this year, we have another compression opportunity there and very strong relationship there, and we're looking forward to growing them for the rest of the year.

    因此,我們在去年第四季引入(onboard)的新合作夥伴表現非常強勁。我們持續成長、穩定,甚至進一步改善這段合作關係。此外,在今年第一季,我們也在壓縮產品方面有另一個機會,且合作關係非常穩固,我們期待在今年剩餘期間持續擴大成長。

  • James Sidoti - Analyst

    James Sidoti - Analyst

  • All right. And can you talk a little bit about pain management? I know there's some reimbursement changes. Have you seen any impact from that? And where do you think pain goes in 2026?

    好的。另外,您能否稍微談談疼痛管理?我知道報銷方面有一些變動。您有看到任何影響嗎?以及您認為到 2026 年疼痛管理會走向何方?

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • We haven't yet seen. There's definitely been some changes in that market. We're pretty excited about that. We do work with our current manufacturers that are in that space to continue to grow. We're working closely with one of our partners on one of the pumps. They're growing their pain team and including some of our third-party payer opportunities as part of their bag and what they're offering for their customers. So we're excited for the year. We haven't seen a lift as of yet. We did add a decent-sized customer over the past couple of months in Q1 of this year. So we continue to be excited for pain management and see what the changes in the market will hold this year.

    我們目前還沒有看到。那個市場確實出現了一些變化。我們對此相當興奮。我們也與目前在該領域的製造商合作,持續推動成長。我們正與其中一位合作夥伴就其中一款幫浦密切合作。他們正在擴編疼痛團隊,並把我們的一些第三方付款方機會納入他們的工具包,以及他們為客戶提供的方案之中。所以我們對今年很期待。截至目前我們尚未看到明顯拉升。不過在今年第一季的過去幾個月裡,我們新增了一位規模相當可觀的客戶。因此我們仍對疼痛管理感到振奮,也會觀察今年市場變化將帶來什麼。

  • James Sidoti - Analyst

    James Sidoti - Analyst

  • And I know you don't like to give quantitative guidance on cash flow, but just qualitatively, can you just give us some direction? Do you think it will be up materially from last year, about the same?

    我知道你們不喜歡對現金流提供量化指引,但就定性角度而言,能否給我們一些方向?你們認為會比去年明顯增加,還是大致相同?

  • Barry Steele - Chief Financial Officer, Executive Vice President

    Barry Steele - Chief Financial Officer, Executive Vice President

  • I would say about the same. I think that the operating cash flow and how we spend it probably similar.

    我會說大致相同。我認為營運現金流以及我們如何運用它,可能都差不多。

  • Operator

    Operator

  • Matt Hewitt, Craig-Hallum Capital Group.

    Matt Hewitt,Craig-Hallum Capital Group。

  • Tollef Kohrman - Analyst

    Tollef Kohrman - Analyst

  • Hello, and thanks for taking the question. This is Tollef Kohrman on for Matt Hewitt. Apologies if you already stated it. I've been going through different calls here this morning. So can you give an update on Chemo Mouthpiece, please? Thanks.

    您好,感謝讓我提問。我是代替 Matt Hewitt 的 Tollef Kohrman。如果你們先前已經提到,先說聲抱歉。我今天早上一直在聽不同的電話會議。所以能否請您更新一下 Chemo Mouthpiece 的情況?謝謝。

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • I sure can. So Chemo Mouthpiece did not receive their current application for coding. That was submitted in 2025 was due out in early of 2026. They did not receive approval for that code. So as we mentioned, as you may remember last year, we did take that out of kind of our pipeline moving forward. It was not in our guidance for this year.

    當然可以。Chemo Mouthpiece 目前這次申請的編碼並未獲核准。該申請於 2025 年提交,原本預計在 2026 年初出結果。他們沒有獲得該代碼的核准。因此如同我們提到的,您可能還記得去年我們已將其從未來的產品管線中移除。它也不在我們今年的指引之中。

  • So we do still have clinics that do love the program. CMP continues to work on reimbursement opportunities for them. So we are still providing that device to patients. We're working with them currently and some of the patients, but I wouldn't expect it in our guidance. And they are looking -- we may look to slow down on some of the referrals for that just until they get some coding.

    不過我們仍有一些診所非常喜歡這個方案。CMP 也持續為他們尋找報銷機會。因此我們仍在向病患提供該裝置。我們目前仍與他們以及部分病患合作,但我不會預期它會納入我們的指引。而且他們正在尋找——在取得一些編碼之前,我們可能會考慮放慢部分轉介。

  • Tollef Kohrman - Analyst

    Tollef Kohrman - Analyst

  • Thank you very much.

    非常感謝。

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • No problem.

    不客氣。

  • Operator

    Operator

  • (Operator Instructions) Benjamin Haynor, Lake Street Capital Markets.

    (接線員指示)Benjamin Haynor,Lake Street Capital Markets。

  • Benjamin Haynor - Analyst

    Benjamin Haynor - Analyst

  • Good morning. Thanks for taking the questions. First off, for me, just with Wound Care, nice to see the trajectory you guys are on there, with it being 6% of revenue now. Looks like that's on its way to double-digits. How should we think about that? How quickly does it get there? What could this ultimately be? Any sort of color that you could provide there would be very helpful.

    早安。感謝讓我提問。首先,就傷口照護而言,很高興看到你們在那邊的成長軌跡,目前已占營收 6%。看起來正朝雙位數邁進。我們應該如何看待這件事?它多快能到達?最終可能會到什麼規模?若能提供一些看法會非常有幫助。

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Yeah, that's a tough question, Ben. We're really excited for the growth and the opportunities that we're seeing ahead. Again, a few new partnerships in compression have been really beneficial for that product line there. I would say with the Lymphederma Patient Treatment Act that came out in reimbursement, we are seeing and, the market is seeing some growth in that compression space and a good CAGR for that market. So we are looking forward to continuing into that as far as, Barry?

    是的,這是個很難的問題,Ben。我們對於成長以及眼前看到的機會感到非常興奮。再次強調,壓迫治療(compression)方面的幾個新合作夥伴,對那條產品線非常有利。我會說,隨著《淋巴水腫病患治療法案》(Lymphedema Patient Treatment Act)在報銷端推出,我們以及市場都看到壓迫治療領域出現一些成長,且該市場有不錯的年複合成長率(CAGR)。因此我們期待持續推進;至於更進一步的部分,Barry?

  • Barry Steele - Chief Financial Officer, Executive Vice President

    Barry Steele - Chief Financial Officer, Executive Vice President

  • I would only add that when we gave our guidance, obviously, the wound care was a very important element to the growth that we're expecting for this year. And as we look at where we would fall into our range, if we fall into the higher end of the range, it's probably going to be PCDs or the compression devices that help us get there, very important for us.

    我只補充一點:當我們給出指引時,顯然傷口照護是我們預期今年成長中非常重要的一個要素。而當我們看我們會落在區間的哪個位置時,如果落在區間的高端,很可能是 PCD 或壓迫裝置幫助我們達成,對我們非常重要。

  • Benjamin Haynor - Analyst

    Benjamin Haynor - Analyst

  • Okay. Got it. That's helpful. And then just with the CMS putting the prior auth requirement in or policy in, I think it kicked in April 13, for these PCDs. Is that something that has impacted you guys in any way, collecting the paperwork? I know that was an issue historically with prior partners, but any issues on that front?

    好的。了解。這很有幫助。另外,CMS 對這些 PCDs 加入事前授權(prior auth)要求或政策,我想是在 4 月 13 日生效。這是否在收集文件方面對你們造成任何影響?我知道過去與某些合作夥伴在歷史上曾是個問題,但在這方面有任何狀況嗎?

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • No, I think that's what's so great about our current partnerships that we do have in that space. We are receiving the appropriate paperwork that we need to bill. The nice part is it's not a change for our current customers that we have. Again, we're a little bit newer to this space, so it's not a change we're going to ask for something that's abnormal for us to ask for. So it's just part of the process that we're really kind of growing with. So no hesitations from us there.

    沒有,我認為這正是我們目前在該領域合作夥伴關係很棒的地方。我們能收到開立帳單所需的適當文件。好的一點是,對我們現有客戶而言這並不是改變。再次強調,我們進入這個領域的時間較短,所以這不是一項變更;我們不會要求一些對我們而言不尋常的資料。因此這只是我們正在共同成長、逐步熟悉的一部分流程。所以我們這邊沒有任何疑慮。

  • Benjamin Haynor - Analyst

    Benjamin Haynor - Analyst

  • Well, that's it for me. Thanks for taking the questions.

    我這邊就這些。感謝讓我提問。

  • Operator

    Operator

  • And ladies and gentlemen, this concludes today's question-and-answer session. I would like to turn the conference back to Carrie Lachance for any closing remarks.

    各位女士、先生,今天的問答環節到此結束。我想把電話會議交回給 Carrie Lachance,請她做結語。

  • Carrie Lachance - President, Chief Executive Officer, Director

    Carrie Lachance - President, Chief Executive Officer, Director

  • Thank you, and thank you, everyone, for joining today's call. We look forward to speaking with you again on our second quarter call, where we will provide an update on our results and progress.

    謝謝,也謝謝各位參加今天的電話會議。我們期待在第二季電話會議上再次與各位交流,屆時我們將更新我們的業績與進展。

  • Operator

    Operator

  • The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    本次電話會議到此結束。感謝各位參加今天的簡報。您現在可以掛線。